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Abstract
Human papillomavirus type-16 (HPV-16) infects mucosal epithelium and is the most common type
found in cervical cancer. HPV-5 infects cornified epithelium and is the most common type found
on normal skin and belongs to the types frequently associated with skin cancers of
Epidermodysplasia verruciformis patients. One factor by which this anatomical tropism could be
determined is the regulation of HPV gene expression in the host cell. The HPV long control region
(LCR) contains cis-responsive elements that regulate HPV transcription and the epithelial tropism
of HPV is determined by epithelial specific constitutive enhancers in the LCR. Since HPV-16 and
other types infecting the mucosa differ in host cell from HPV types infecting skin, it has been
hypothesized that it is the combination of ubiquitous transcription factors working in concert in
the host cell that determines the cell-type-specific expression. To study if HPV tropism could be
determined by differences in transcriptional regulation we have cloned the transcriptional
regulating region, LCR, from HPV-16 and HPV-5 and studied the activation of a reporter gene in
cell lines with different origin. To analyse promoter activity we transfected the plasmids into four
different cell lines; HaCaT, C33A, NIKS and W12E and the efficiency of HPV-5 and HPV-16 LCR
in the different cell lines was compared. In HaCaT cells, with a skin origin, the HPV-5 LCR was two-
fold more efficient in transcriptional activation compared to the HPV-16 LCR. In cervical W12E
cells the HPV-16 LCR was almost 2-fold more effective in activating transcription compared to the
HPV-5 LCR. The ability to initiate transcription in the other cell lines was independent on cell origin
and HPV-type.
Findings
Papillomaviruses belong to the Papillomaviridae  family
and consist of a large family of non-enveloped double
stranded DNA viruses that infect the cutaneous or
mucosal epithelia of a dozen vertebrate species with a
strict species tropism. Over 100 human papillomavirus
(HPV) types have been completely described and identi-
fied in human tissues and they together with animal pap-
illomaviruses are divided into 18 genera based on their
nucleotide sequence identity of the major capsid protein
L1 open reading frame (ORF) [1]. HPV-16 infects mucosal
cells and belongs to the alpha-papillomavirus genus, spe-
cies 9 [1] and is the most common type found in cervical
cancer but does also cause condyloma and other infec-
tions of the genital, oral and respiratory tracts [2]. HPV-5
infects skin and is the most common type found on nor-
mal skin all around the world [3]. It belongs to species 1
of the beta-papillomavirus genus [1] and is associated
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with skin cancers in patients diagnosed with Epidermodys-
plasia verruciformis. All HPVs cause lesions of epithelial
origin, but nothing is known regarding why certain HPVs
are only detected in skin while some are only found in
mucosal cells. It has been suggested that the different biol-
ogy of transcriptional regulation of alpha and beta HPVs
could be important for this tropism [4].
Once HPV has entered the cell, the viral DNA is trans-
ported to the nucleus for transcription and replication.
The long control region (LCR) of HPV contains enhancer
elements responsive to cellular factors and virally encoded
transcriptional regulatory factors and is positioned
between the L1 and E6 gene. The transcription is tightly
regulated by the differentiation state of the infected epi-
thelial cell [5-9] and the location of transcription initia-
tion is found in the LCR. All papillomavirus LCRs studied
so far contain epithelial specific constitutive enhancers
[10] that contribute to the epithelial tissue tropism of
HPVs. Most HPV-types have a promoter in front of the E6
gene in common [11,12]. For HPV-16, P97 is the major
promoter which directs the expression of E6 and E7 as
well as several other early gene products. It is analogous to
the P97 of HPV-31 and P105 of HPV-18. For HPV-5, two
promoters are suggested to exist within the LCR, an early
E6 promoter and a late promoter [13]. Their positions are
most probably similar to the closely related HPV-8 pro-
moters P175 and P7535 [12,14]. In alpha HPVs transcription
starts with the interaction of transcription factors with the
TATA-box and Sp1 binding site on E6 promotor [15].
Depending on the HPV type these enhancers differ in
quantity, arrangement and type. A synergism between fac-
tors like AP-1, NF-1, TEF-1 and Sp1 and the composition
of their subunits seem to play an important role for HPV
transcription in the epithelial cell layers where HPV is
actively transcribed [16-19].
Since mucosal and cutaneous epithelium has been shown
to express different proteins [20] it is conceivable that
cutaneous HPV-5 and mucosal HPV-16 are exposed to a
different transcriptional environment. The HPV LCR may
also have different capacity to cooperate with cellular fac-
tors from the host cell depending on HPV type and cell
line origin. To study if tropism could in part be deter-
mined by differences in transcriptional regulation we have
cloned the transcriptional regulating region, LCR, from
HPV-5 and HPV-16 and studied the activation of a
reporter gene in cell lines with different origin.
The LCR fragment was cloned from the end of the viral L1
gene to the beginning of E6. The HPV-5 LCR fragment (nt
7468-199) ended with the first ATG of the E6 open read-
ing frame (ORF), including the suggested HPV-5 P175 (E6)
and P7535 (late) promotors. The HPV-16 LCR fragment (nt
7155-103) contained the P97  major promoter in the
beginning of the E6 gene. The correct cloning of the LCR-
fragments was verified through sequence analysis. To ana-
lyse promoter activity we transfected the plasmids into
HaCaT cells from adult trunk skin [21], C33A cells from
the cervix [22], a spontaneously immortalized keratinoc-
yte cell line from human foreskin NIKS (clone SG1WT)
[23] and W12E (clone 20850) from a natural human cer-
vical lesion [24]. Both the W12E and the NIKS cells con-
tained HPV-16 episomal DNA and were cultured as
described [25,26]. When we compared the efficiency of
the HPV LCR constructs we found that the HPV-5 LCR
activated transcription 2-fold stronger in HaCaT cells with
a skin origin than either of the HPV-16 LCRs (Fig 1). The
opposite was found for W12E cells from cervical mucosa.
Here the HPV-16 LCR was almost 2-fold better than HPV-
5 LCR in activating transcription (Fig. 1). In the other cell
lines there were only small differences (Fig 1).
A factor determining HPV tropism could be viral entry
into the host cell and we have found some differences in
virus entry dependent on HPV type and cell origin (Mistry
et al., manuscript submitted), but the anatomical tropism
could not be completely explained by these results and
other functional differences, like transcriptional activa-
tion, should be important for this tropism. The LCR of
HPV-16 is much longer (832 bp) than HPV-5 (478 bp)
and has several additional binding sites for transcription
factors when compared [27]. The LCR of these two types
have also been analysed in silico and shown to have differ-
ent sets of transcription factor binding sites [4]. Common
binding sites in the LCR include those for TFIID binding
to canonical TATA boxes located approximately 30 bp
upstream from the early start sites. Upstream of these
sequences are NF-1 and AP-1 binding sites, and these are
found in all HPV types studied [10]. A number of addi-
tional transcription factors shared among many HPV
types have been described that bind to the LCR, e.g. Sp-1,
TEF-1, Oct-1, YY1 and CDP as well as glucocorticoid
responsive elements [16]. All alpha HPVs seem to have
Sp-1 activated promoters, while there are no Sp-1 sites at
the E6 promotors for the beta HPV-5 and HPV-8 [10]. The
HPV-16 LCR also contains nuclear matrix attachment sites
which could be important for controlling HPV expression
[28]. HaCat cells have previously been shown to support
HPV-16 LCR activation of the P97 promoter [10]. P97
seems to be the major early promoter in HPV-16 although
other transcription initiator sites have been observed. Two
promoters are described within the HPV-5 LCR, one just
in front of the E6 gene and the other in the middle of the
LCR [13]. The last is a late promoter that is up-regulated
in stratum granulosum, leading to L1 and L2 expression
and possibly E2 expression at low levels [13]. None of the
cell lines used here was differentiated, so this region
should not initiate transcription. More likely the HPV-5
LCR activation of expression was a result of an active E6Virology Journal 2007, 4:27 http://www.virologyj.com/content/4/1/27
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promoter. To certify this, transfections of HPV-5 LCR frag-
ments containing either the early or the late promoter in
differentiated cells could be performed. Previously, the
transcriptional activity of the HPV-5 LCR fragment con-
taining only the predicted enhancer, but lacking the 5'-
and 3'-LCR, showed similar activity as the HPV-16
enhancer fragment in HaCat cells, but not in genital HeLa
cells where HPV-16 was 10-fold stronger [10]. The HPV-
16 LCR fragment containing the enhancer and promoter
region but lacking the 5'-LCR was compared to beta HPV-
8, from species 1 and both had similar transcriptional
activation in HeLa cells but surprisingly HPV-16 was 2-
fold stronger in HaCaT cells [10]. Our constructs con-
tained the complete HPV-5 LCR from the end of L1 to the
beginning of E6 and in HaCaT cells the transcriptional
activation of HPV-5 was 2-fold stronger than HPV-16,
although the levels were very low compared to the control
CMV promoter we used (data not shown).
The HPV E2 protein can regulate the transcription from
adjacent promoters by interacting with transcription fac-
tors like TATA-box binding protein and Sp1 [29]. E2 rec-
ognizes a palindrome sequence positioned at various sites
on LCR and the alpha-papillomavirus genus has four
binding sites for E2, while members of the beta-papillo-
mavirus genus differ regarding number and positions of
E2 binding sites. Two E2 binding sites are found adjacent
to the E6 promoter in HPV-16, but not in HPV-5. We did
not study the effect of E2, but since the NIKS and W12E
cells contained episomal copies of HPV-16 we can not
rule out an effect of E2 on our reporter constructs,
although unlikely. To conclude, differences were found
between HPV-5 and HPV-16 transcriptional activation in
HaCaT and W12E cells. The LCR of HPV-5 was more effec-
tive than the LCR from HPV-16 in initiating transcription
in HaCaT cells originally derived from skin and the HPV-
16 LCR was more effective than the HPV-5 LCR in cervical
W12E cells.
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